 Treatment Market Size.webp)
Irritable Bowel Syndrome Treatment Market size is estimated at USD 3.6 billion in 2024 and is estimated to reach USD 10.7 billion by the end of 2037, expanding at a CAGR of 8.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of irritable bowel syndrome treatment is evaluated at USD 3.9 billion.
The rise in sedentary lifestyles and poor eating habits are some of the major reasons boosting the prevalence rates of irritable bowel syndrome, which is subsequently driving high demand for IBS treatment solutions. For instance, the International Foundation for Gastrointestinal Disorders (IFFGD) estimates that around 5 % to 10% of the population around the globe are living with irritable bowel syndrome issues. Around 20% to 40% of visits to gastrointestinal clinics are due to irritable bowel syndrome issues.
The rising awareness programs and increasing research funding are leading to the development of advanced irritable bowel syndrome therapeutic drugs. Globally, April is commemorated as irritable bowel syndrome awareness month. Several hospitals and clinics run free diagnosis and awareness campaigns during this period. Such initiatives are set to fuel the irritable bowel syndrome treatment market growth in the coming years.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.8% |
|
Base Year Market Size (2024) |
USD 3.6 billion |
|
Forecast Year Market Size (2037) |
USD 10.7 billion |
|
Regional Scope |
|
Dosage Form (Tablets, Liquid, Powder)
The tablets segment in the irritable bowel syndrome treatment market is expected to capture 68.2% of the revenue share by the end of 2037, owing to their convenience and dosage accuracy. Tablets are easy to consume and carry as they are available in accurate and precise dosages, which makes them a preferred choice for many patients. Tablets typically have a longer shelf life compared to other formulations such as liquid and powder. This portability and stability are making them more appealing to patients and driving their demand growth.
The growing trend towards self-medication and over-the-counter availability for certain IBS drugs is making tablets a more accessible option for patients seeking immediate relief.
Distribution Channel (Brick & Mortar, E-commerce)
The brick and mortar segment is estimated to hold 67.5% of the global irritable bowel syndrome treatment market share through 2037. The easy accessibility is one of the prime reasons driving the sales of irritable bowel syndrome drugs through brick and mortar pharmacies. Physical pharmacies are easily accessible for patients who require immediate relief or ongoing management of irritable bowel syndrome symptoms. Many patients prefer to consult with a pharmacist face to face especially when dealing with sensitive health issues.
Also, many IBS patients rely on insurance coverage for prescription medications, brick and mortar pharmacies can facilitate the processing of insurance claims, making them a prime preference for medicine distribution. The sales of irritable bowel syndrome drugs through brick and mortar distribution channels were valued at USD 2.0 billion in 2023.
Our in-depth analysis of the irritable bowel syndrome treatment market includes the following segments:
|
Condition
|
|
|
Drug Class |
|
|
Dosage Form |
|
|
Distribution Channel |
|
North America Market Forecast
North America IBS treatment market is expected to capture a share of 36.4% through 2037 owing to the presence of advanced healthcare facilities and ongoing advancements in the pharma sector. The presence of early adopters in the region is driving the sales of innovative irritable bowel syndrome drugs. The North America irritable bowel syndrome treatment market is estimated to increase from USD 1.5 billion in 2025 to USD 3.9 billion by 2037.
The U.S. IBS treatment market is forecasted to rise at a CAGR of 8.3% and reach USD 3.6 billion by 2037. The strong presence of key market players is fuelling the sales of irritable bowel syndrome drugs in the country. In Canada, the increasing prevalence of irritable bowel syndrome issues is anticipated to boost the market growth during the forecasted period. The Canadian Digestive Health Foundation reveals that the prevalence rate of irritable bowel syndrome is around 18% in the country.
Asia Pacific Market Statistics
Asia Pacific irritable bowel syndrome treatment market is expected to increase at a fast pace during the forecasted period owing to the increasing spending on healthcare infrastructure, expanding pharmaceutical manufacturing companies, and growing cases of obesity leading to IBS issues. India, Japan, South Korea, and China are the most profitable economies for irritable bowel syndrome drug manufacturers.
The high investments in healthcare infrastructure development projects and favorable government policies on drug production are generating profitable opportunities for irritable bowel syndrome therapeutic solution producers in India. The country is emerging as a medical tourism hub owing to the presence of cost-effective and advanced technologies and skilled expertise for various treatments. For instance, the local government is focusing on increasing its Pradhan Mantri Bhartiya Jan Aushadhi Kendras to 10,500 by March 2025. This is set to boost the sales of IBS drugs in the country.
 Treatment Market Share.webp)
Key players in the irritable bowel syndrome treatment market are adopting several organic and inorganic tactics to earn high profits. Leading companies are investing heavily in R&D for the production of advanced and reliable irritable bowel syndrome drugs to maximize their revenue shares. They are also collaborating with other players and research organizations to attract a wider consumer base through innovations. Industry giants are also employing regional expansion strategies to increase their market reach.
Some of the key players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?